RMR Wealth Builders Buys 265 Shares of Vertex Pharmaceuticals Incorporated $VRTX

RMR Wealth Builders raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,100 shares of the pharmaceutical company’s stock after acquiring an additional 265 shares during the quarter. RMR Wealth Builders’ holdings in Vertex Pharmaceuticals were worth $2,271,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VRTX. GAMMA Investing LLC raised its holdings in Vertex Pharmaceuticals by 60,572.3% in the 1st quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company’s stock valued at $1,175,722,000 after acquiring an additional 2,421,073 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock worth $1,414,331,000 after purchasing an additional 1,226,527 shares during the period. Nuveen LLC bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth approximately $484,053,000. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 17.2% during the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock worth $2,454,373,000 after purchasing an additional 744,680 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 28.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company’s stock worth $860,650,000 after purchasing an additional 398,460 shares during the period. 90.96% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Bruce I. Sachs bought 5,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $394.53 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The firm has a market capitalization of $101.15 billion, a P/E ratio of 28.20 and a beta of 0.44. The company’s 50 day moving average price is $422.66 and its two-hundred day moving average price is $453.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter last year, the business posted ($12.83) earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Guggenheim lowered their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Erste Group Bank cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, August 5th. Stifel Nicolaus decreased their price objective on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating on the stock in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald decreased their price objective on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $496.05.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.